stockrow
Friday 6 November 2026
Export MIRM’s income statement to Excel — free account
Mirum Pharmaceuticals, Inc.
MIRM Healthcare Biotechnology
Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024.
- Revenue
- +39.6%
- EPS
- −1,136.8%
- Free cash flow
- −114.2%
- Total debt
- +136.4%
Quarter to September 2026, against a year earlier
93.82
0.28
+0.30%
Follow MIRM
Alert me
Mirum Pharmaceuticals, Inc. (MIRM) Revenue growth
Mirum Pharmaceuticals, Inc.'s revenue growth over the twelve months to 30 September 2026 was 42.2%, down 12.6 percentage points from fiscal 2025 (54.7%). That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 54.7% | (26.02) |
| FY2024 | 80.8% | (61.09) |
| FY2023 | 141.9% | (160.81) |
| FY2022 | 302.7% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 39.6% | 1.71 |
| Jun 2026 | 37.9% | (5.36) |
| Mar 2026 | 43.3% | (6.53) |
| Dec 2025 | 49.8% | 2.64 |
| 14 more quarters | Free account |
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| CGON CG Oncology, Inc. compare | 840.8% |
| MIRM Mirum Pharmaceuticals, Inc. | 42.2% |
| LGND Ligand Pharmaceuticals Incorporated compare | 1.03% |
| IONS Ionis Pharmaceuticals, Inc. compare | −7.41% |
| PTCT PTC Therapeutics, Inc. compare | −35.1% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
| IMVT Immunovant, Inc. compare | — |
| ORKA Oruka Therapeutics, Inc. compare | — |
| KOD Kodiak Sciences Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on MIRM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement